Insider Buying: Talphera (NASDAQ:TLPH) CEO Purchases $85,344.84 in Stock

Talphera, Inc. (NASDAQ:TLPH) CEO Vincent Angotti purchased 105,364 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The stock was purchased at an average price of $0.81 per share, for a total transaction of $85,344.84. Following the purchase, the chief executive officer owned 586,954 shares in the company, valued at $475,432.74. This represents a 21.88% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Talphera Trading Down 3.9%

Talphera stock opened at $0.78 on Monday. Talphera, Inc. has a 12 month low of $0.38 and a 12 month high of $1.57. The stock has a fifty day simple moving average of $1.00 and a two-hundred day simple moving average of $0.99. The firm has a market cap of $36.20 million, a price-to-earnings ratio of -2.04 and a beta of 0.46.

Analysts Set New Price Targets

Several analysts have issued reports on TLPH shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Talphera in a report on Wednesday, January 21st. Wall Street Zen raised Talphera to a “hold” rating in a research report on Saturday, November 1st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $6.00.

Hedge Funds Weigh In On Talphera

Institutional investors have recently added to or reduced their stakes in the company. AIGH Capital Management LLC bought a new position in Talphera during the third quarter valued at $3,979,000. Group One Trading LLC increased its holdings in shares of Talphera by 3,224.0% in the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock worth $27,000 after buying an additional 29,500 shares during the last quarter. Rosalind Advisors Inc. raised its position in shares of Talphera by 118.9% during the 3rd quarter. Rosalind Advisors Inc. now owns 4,385,757 shares of the company’s stock valued at $3,917,000 after buying an additional 2,381,818 shares in the last quarter. Dauntless Investment Group LLC bought a new position in shares of Talphera in the 3rd quarter valued at about $89,000. Finally, Virtu Financial LLC bought a new position in shares of Talphera in the 3rd quarter valued at about $29,000. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.